Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1-12
Number of pages	12
Journal	Health Technology Assessment
Volume	15
Issue number	Supp 1
Publication status	Published - May 2011

Access to Document

@article{951c7e13e51248cc8746f8440ad613e2,

title = "Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.",

author = "M Rodgers and M Soares and D Epstein and H Yang and D Fox and A Eastwood",

year = "2011",

month = may,

language = "English",

volume = "15",

pages = "1--12",

journal = "Health Technology Assessment",

issn = "2046-4924",

publisher = "NHS National Institute for Health Research",

number = "Supp 1",

}

TY - JOUR

T1 - Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

AU - Rodgers, M

AU - Soares, M

AU - Epstein, D

AU - Yang, H

AU - Fox, D

AU - Eastwood, A

PY - 2011/5

Y1 - 2011/5

UR - http://www.scopus.com/inward/record.url?scp=84863520583&partnerID=8YFLogxK

M3 - Article

SN - 2046-4924

VL - 15

SP - 1

EP - 12

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - Supp 1

ER -